A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

Purpose Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2008-12, Vol.112 (3), p.533-543
Hauptverfasser:	Cameron, David, Casey, Michelle, Press, Michael, Lindquist, Deborah, Pienkowski, Tadeusz, Romieu, C. Gilles, Chan, Stephen, Jagiello-Gruszfeld, Agnieszka, Kaufman, Bella, Crown, John, Chan, Arlene, Campone, Mario, Viens, Patrice, Davidson, Neville, Gorbounova, Vera, Raats, Johannes Isaac, Skarlos, Dimosthenis, Newstat, Beth, Roychowdhury, Debasish, Paoletti, Paolo, Oliva, Cristina, Rubin, Stephen, Stein, Steven, Geyer, Charles E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor Breast cancer Breast Neoplasms - drug therapy Cancer research Cancer therapies Capecitabine Clinical Trial Clinical trials Comparative studies Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease Progression Drug therapy Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Humans Medicine Medicine & Public Health Middle Aged Neoplasm Metastasis Oncology Protein-Tyrosine Kinases - antagonists & inhibitors Quinazolines - administration & dosage Trastuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!